8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Feb 12, 2026·SEC
Alnylam Pharmaceuticals, Inc.(ALNY)Earnings, Financials & Key Ratios
ALNY•NASDAQ
119.4× P/E·Price updated Jun 19, 2026
AboutAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$3.71B+65.2%
- EBITDA$557M+563.5%
- Net Income$314M+212.8%
- EPS (Diluted)2.33+206.9%
- Gross Margin81.77%-4.5%
- EBITDA Margin15%+380.6%
- Operating Margin13.51%+271.7%
- Net Margin8.45%+168.3%
- ROE73.28%+117.7%
ALNY Key Insights
Alnylam Pharmaceuticals, Inc. (ALNY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 49.8%
✗Weaknesses
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 47.5x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ALNY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALNY Price & Volume
Alnylam Pharmaceuticals, Inc. (ALNY) stock price & volume — 10-year historical chart
Loading chart...
ALNY Growth Metrics
Alnylam Pharmaceuticals, Inc. (ALNY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years56.89%
5 Years49.77%
3 Years52.98%
TTM82.57%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM314.02%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM301.44%
Return on Capital
10 Years-25.97%
5 Years-10.53%
3 Years-0.23%
Last Year15.31%
ALNY Recent Earnings
Alnylam Pharmaceuticals, Inc. (ALNY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.51+73.2%
$0.87
Rev
$1.2B+4.6%
$1.1B
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.82-29.3%
$1.16
Rev
$1.1B-4.5%
$1.1B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$2.90+416.9%
$0.56
Rev
$1.2B+30.2%
$959M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.32+158.9%
$0.54
Rev
$774M+16.7%
$663M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.51vs $0.87+73.2% | $1.2Bvs $1.1B+4.6% |
| Q1 2026 | Feb 12, 2026 | $0.82vs $1.16-29.3% | $1.1Bvs $1.1B-4.5% |
| Q4 2025 | Oct 30, 2025 | $2.90vs $0.56+416.9% | $1.2Bvs $959M+30.2% |
| Q3 2025 | Jul 31, 2025 | $0.32vs $0.54+158.9% | $774Mvs $663M+16.7% |
Based on last 12 quarters of dataView full earnings history →
ALNY Peer Comparison
Alnylam Pharmaceuticals, Inc. (ALNY) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 MRNA | 25.37B | 63.96 | -8.81 | -39.23% | -143.55% | -36.73% | 0.22 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 |
Compare ALNY vs Peers
Alnylam Pharmaceuticals, Inc. (ALNY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALNY Income Statement
Alnylam Pharmaceuticals, Inc. (ALNY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 89.91M | 74.91M | 219.75M | 492.85M | 844.29M | 1.04B | 1.83B | 2.25B | 3.71B | 4.29B |
Revenue Growth % | 90.66% | -16.69% | 193.36% | 124.28% | 71.31% | 22.88% | 76.23% | 22.97% | 65.19% | 82.57% |
Cost of Goods Sold | 13.37M | 1.8M | 25.06M | 78.05M | 140.14M | 168.82M | 310.41M | 323.37M | 677.17M | 819.03M |
COGS % of Revenue | 14.87% | 2.41% | 11.4% | 15.84% | 16.6% | 16.27% | 16.98% | 14.38% | 18.23% | - |
Gross Profit | 76.55M▲ 0% | 73.11M▼ 4.5% | 194.69M▲ 166.3% | 414.8M▲ 113.1% | 704.14M▲ 69.8% | 868.6M▲ 23.4% | 1.52B▲ 74.8% | 1.92B▲ 26.8% | 3.04B▲ 57.8% | 3.47B▲ 0% |
Gross Margin % | 85.13% | 97.59% | 88.6% | 84.16% | 83.4% | 83.73% | 83.02% | 85.62% | 81.77% | 80.89% |
Gross Profit Growth % | 62.31% | -4.49% | 166.31% | 113.06% | 69.75% | 23.36% | 74.75% | 26.81% | 57.76% | - |
Operating Expenses | 590M | 887.78M | 1.13B | 1.24B | 1.41B | 1.65B | 1.8B | 2.1B | 2.54B | 2.72B |
OpEx % of Revenue | 656.2% | 1185.16% | 516.1% | 252.25% | 167.34% | 159.4% | 98.46% | 93.48% | 68.26% | - |
Selling, General & Admin | 199.37M | 382.36M | 479M | 588.42M | 620.64M | 770.66M | 795.65M | 975.53M | 1.21B | 1.29B |
SG&A % of Revenue | 221.73% | 510.44% | 217.98% | 119.39% | 73.51% | 74.29% | 43.52% | 43.39% | 32.6% | - |
Research & Development | 390.63M | 505.42M | 655.11M | 654.82M | 792.16M | 883.01M | 1B | 1.13B | 1.32B | 1.42B |
R&D % of Revenue | 434.46% | 674.72% | 298.12% | 132.86% | 93.83% | 85.12% | 54.94% | 50.09% | 35.66% | - |
Other Operating Expenses | -3.02M | 4.17M | 0 | 0 | -2.05M | 0 | 0 | 0 | 0 | 1000K |
Operating Income | -500.09M▲ 0% | -814.67M▼ 62.9% | -939.43M▼ 15.3% | -828.44M▲ 11.8% | -708.65M▲ 14.5% | -785.07M▼ 10.8% | -282.18M▲ 64.1% | -176.88M▲ 37.3% | 501.58M▲ 383.6% | 752.14M▲ 0% |
Operating Margin % | -556.2% | -1087.56% | -427.5% | -168.09% | -83.94% | -75.68% | -15.43% | -7.87% | 13.51% | 17.54% |
Operating Income Growth % | -17.78% | -62.91% | -15.31% | 11.81% | 14.46% | -10.78% | 64.06% | 37.31% | 383.56% | - |
EBITDA | -486.72M | -808.24M | -922.26M | -793.67M | -661.09M | -740.6M | -228.12M | -120.22M | 557.24M | 677.12M |
EBITDA Margin % | -541.33% | -1078.97% | -419.68% | -161.03% | -78.3% | -71.39% | -12.48% | -5.35% | 15% | 15.79% |
EBITDA Growth % | -18.87% | -66.06% | -14.11% | 13.94% | 16.7% | -12.03% | 69.2% | 47.3% | 563.53% | 1271.19% |
D&A (Non-Cash Add-back) | 13.37M | 6.43M | 17.18M | 34.77M | 47.57M | 44.47M | 54.05M | 56.67M | 55.66M | 41.25M |
EBIT | -500.09M | -760.67M | -885.25M | -771.1M | -709.12M | -971.02M | -312.3M | -235.52M | 501.58M | 572.34M |
Net Interest Income | 12.24M | 29.26M | 33.45M | -72.69M | -141.44M | -131.16M | -25.66M | -19.87M | -141.16M | -173.87M |
Interest Income | 12.24M | 29.26M | 33.45M | 11.81M | 1.58M | 24.81M | 95.56M | 121.99M | 111.47M | 109.39M |
Interest Expense | 0 | 0 | 0 | 84.5M | 143.02M | 155.97M | 121.22M | 141.86M | 252.63M | 283.27M |
Other Income/Expense | 9.21M | 54M | 54.18M | -27.16M | -143.49M | -341.92M | -151.34M | -200.49M | -178.43M | -165.74M |
Pretax Income | -490.87M▲ 0% | -760.67M▼ 55.0% | -885.25M▼ 16.4% | -855.6M▲ 3.3% | -852.14M▲ 0.4% | -1.13B▼ 32.3% | -433.52M▲ 61.5% | -377.38M▲ 13.0% | 323.15M▲ 185.6% | 586.4M▲ 0% |
Pretax Margin % | -545.95% | -1015.48% | -402.85% | -173.6% | -100.93% | -108.63% | -23.71% | -16.79% | 8.7% | 13.68% |
Income Tax | 0 | 823K | 863K | 2.68M | 680K | 4.16M | 6.72M | -99.22M | 9.4M | -22.14M |
Effective Tax Rate % | 0% | -0.11% | -0.1% | -0.31% | -0.08% | -0.37% | -1.55% | 26.29% | 2.91% | -3.78% |
Net Income | -490.87M▲ 0% | -761.5M▼ 55.1% | -886.12M▼ 16.4% | -858.28M▲ 3.1% | -852.82M▲ 0.6% | -1.13B▼ 32.6% | -440.24M▲ 61.1% | -278.16M▲ 36.8% | 313.75M▲ 212.8% | 577.22M▲ 0% |
Net Margin % | -545.95% | -1016.58% | -403.24% | -174.15% | -101.01% | -109.04% | -24.08% | -12.37% | 8.45% | 13.46% |
Net Income Growth % | -19.69% | -55.13% | -16.36% | 3.14% | 0.64% | -32.64% | 61.08% | 36.82% | 212.79% | 314.02% |
Net Income (Continuing) | -490.87M | -761.5M | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M | -278.16M | 313.75M | 608.54M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -5.42▲ 0% | -7.57▼ 39.7% | -8.11▼ 7.1% | -7.46▲ 8.0% | -7.20▲ 3.5% | -9.30▼ 29.2% | -3.52▲ 62.2% | -2.18▲ 38.1% | 2.33▲ 206.9% | 4.18▲ 0% |
EPS Growth % | -13.15% | -39.67% | -7.13% | 8.01% | 3.49% | -29.17% | 62.15% | 38.07% | 206.88% | 301.44% |
EPS (Basic) | -5.42 | -7.57 | -8.11 | -7.46 | -7.20 | -9.30 | -3.52 | -2.18 | 2.39 | - |
Diluted Shares Outstanding | 90.55M | 100.59M | 109.26M | 114.99M | 118.45M | 121.69M | 124.91M | 127.65M | 134.68M | 138.23M |
Basic Shares Outstanding | 90.55M | 100.59M | 109.26M | 114.99M | 118.45M | 121.69M | 124.91M | 127.65M | 131M | 132.89M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ALNY Balance Sheet
Alnylam Pharmaceuticals, Inc. (ALNY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.76B | 1.2B | 1.72B | 2.61B | 2.81B | 2.69B | 2.98B | 3.3B | 4.05B | 4.22B |
Cash & Short-Term Investments | 1.69B | 1.08B | 1.54B | 1.87B | 2.44B | 2.19B | 2.44B | 2.69B | 2.91B | 3.01B |
Cash Only | 645.36M | 420.15M | 547.18M | 496.58M | 819.98M | 866.39M | 812.69M | 966.43M | 1.66B | 1.71B |
Short-Term Investments | 1.05B | 664.01M | 988.98M | 1.38B | 1.62B | 1.33B | 1.63B | 1.73B | 1.25B | 1.3B |
Accounts Receivable | 34M | 18.76M | 43.01M | 602.41M | 198.57M | 237.96M | 327.79M | 405.31M | 777.57M | 883.96M |
Days Sales Outstanding | 138.03 | 91.41 | 71.44 | 446.14 | 85.85 | 83.72 | 65.44 | 65.8 | 76.42 | 67.97 |
Inventory | 0 | 24.07M | 56.35M | 75.2M | 86.36M | 128.96M | 89.15M | 78.51M | 82.72M | 84.03M |
Days Inventory Outstanding | - | 4.88K | 820.65 | 351.67 | 224.93 | 278.83 | 104.82 | 88.62 | 44.59 | 34.96 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 132.92M | 126.38M | 116.96M | 281.89M | 242.1M |
Total Non-Current Assets | 229.99M | 374.11M | 679.27M | 792.28M | 834.73M | 854.11M | 847.18M | 944.7M | 915.67M | 910.24M |
Property, Plant & Equipment | 181.9M | 320.66M | 646.38M | 706.51M | 733.63M | 738.63M | 725.79M | 693.93M | 708.06M | 707.56M |
Fixed Asset Turnover | 0.49x | 0.23x | 0.34x | 0.70x | 1.15x | 1.40x | 2.52x | 3.24x | 5.25x | 6.12x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 13.92M | 44.83M | 14.82M | 0 | 0 | 0 | 0 | 0 | 0 | 53.87M |
Other Non-Current Assets | 34.17M | 8.62M | 18.07M | 85.77M | 101.09M | 115.48M | 111.29M | 133.9M | 81.63M | 85.72M |
Total Assets | 1.99B▲ 0% | 1.57B▼ 21.1% | 2.4B▲ 52.1% | 3.41B▲ 42.2% | 3.64B▲ 6.9% | 3.55B▼ 2.7% | 3.83B▲ 8.0% | 4.24B▲ 10.7% | 4.97B▲ 17.1% | 5.13B▲ 0% |
Asset Turnover | 0.05x | 0.05x | 0.09x | 0.14x | 0.23x | 0.29x | 0.48x | 0.53x | 0.75x | 0.88x |
Asset Growth % | 57.96% | -21.05% | 52.09% | 42.25% | 6.93% | -2.66% | 7.99% | 10.71% | 17.13% | 68.12% |
Total Current Liabilities | 144.25M | 179.49M | 352.59M | 585.27M | 695.71M | 767.91M | 967.79M | 1.19B | 1.47B | 1.35B |
Accounts Payable | 28.36M | 59.71M | 49.88M | 51.97M | 73.43M | 98.09M | 55.52M | 88.42M | 115.72M | 126.63M |
Days Payables Outstanding | 774.26 | 12.09K | 726.5 | 243.01 | 191.24 | 212.09 | 65.28 | 99.8 | 62.37 | 51.51 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 113.02M | 0 | 45.66M |
Deferred Revenue (Current) | 41.7M | 3.5M | 77.82M | 127.21M | 149.48M | 42.1M | 102.75M | 55.48M | 4.84M | 25.68M |
Other Current Liabilities | 35.81M | 40.87M | 68.3M | 110.75M | 130.66M | 170.98M | 177.16M | 214.4M | 477.26M | 1.17B |
Current Ratio | 12.23x | 6.69x | 4.87x | 4.47x | 4.04x | 3.51x | 3.08x | 2.78x | 2.76x | 3.13x |
Quick Ratio | 12.23x | 6.56x | 4.71x | 4.34x | 3.91x | 3.34x | 2.99x | 2.71x | 2.71x | 3.06x |
Cash Conversion Cycle | - | -7.13K | 165.58 | 554.8 | 119.54 | 150.46 | 104.98 | 54.62 | 58.63 | 51.43 |
Total Non-Current Liabilities | 84.05M | 93.34M | 603.85M | 1.81B | 2.36B | 2.94B | 3.08B | 2.99B | 2.71B | 2.7B |
Long-Term Debt | 30M | 30M | 0 | 191.28M | 675.7M | 1.02B | 1.02B | 2.36B | 1.01B | 1.23B |
Capital Lease Obligations | 0 | 0 | 276.13M | 293.04M | 281.35M | 261.34M | 243.1M | 229.54M | 225.09M | 672.95M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10.97M | 62.88M | 9.33M | 1.1B | 1.25B | 1.46B | 1.63B | 398.11M | 1.48B | 1.48B |
Total Liabilities | 228.3M | 272.84M | 956.44M | 2.39B | 3.06B | 3.7B | 4.05B | 4.17B | 4.18B | 4.05B |
Total Debt | 30M | 30M | 303.82M | 521.19M | 997.59M | 1.32B | 1.31B | 2.74B | 1.28B | 1.27B |
Net Debt | -615.36M | -390.15M | -243.35M | 24.61M | 177.62M | 453.85M | 492.7M | 1.78B | -378.86M | -437.72M |
Debt / Equity | 0.02x | 0.02x | 0.21x | 0.51x | 1.70x | - | - | 40.89x | 1.62x | 1.18x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 2.29x | 1.88x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.68x | -0.65x |
Interest Coverage | - | - | - | -9.13x | -4.96x | -6.23x | -2.58x | -1.66x | 1.99x | 2.02x |
Total Equity | 1.77B▲ 0% | 1.3B▼ 26.3% | 1.44B▲ 10.5% | 1.02B▼ 29.4% | 588.2M▼ 42.1% | -158.22M▼ 126.9% | -220.64M▼ 39.5% | 67.09M▲ 130.4% | 789.18M▲ 1076.3% | 1.08B▲ 0% |
Equity Growth % | 91.96% | -26.29% | 10.5% | -29.36% | -42.12% | -126.9% | -39.45% | 130.41% | 1076.33% | 10801.4% |
Book Value per Share | 19.51 | 12.94 | 13.17 | 8.84 | 4.97 | -1.30 | -1.77 | 0.53 | 5.86 | 7.78 |
Total Shareholders' Equity | 1.77B | 1.3B | 1.44B | 1.02B | 588.2M | -158.22M | -220.64M | 67.09M | 789.18M | 1.08B |
Common Stock | 997K | 1.01M | 1.12M | 1.16M | 1.2M | 1.24M | 1.26M | 1.29M | 1.32M | 1.33M |
Retained Earnings | -2.15B | -2.84B | -3.73B | -4.59B | -5.44B | -6.57B | -7.01B | -7.29B | -6.7B | -6.5B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -34.43M | -33.21M | -36.52M | -43.62M | -33.26M | -44.65M | -23.38M | -34.52M | -20.1M | -24.89M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALNY Cash Flow Statement
Alnylam Pharmaceuticals, Inc. (ALNY) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -382.79M | -562.62M | -278.43M | -614.96M | -641.69M | -541.27M | 104.16M | -8.31M | 524.08M | 712.9M |
Operating CF Margin % | -425.73% | -751.08% | -126.7% | -124.78% | -76% | -52.18% | 5.7% | -0.37% | 14.11% | - |
Operating CF Growth % | -24.4% | -46.98% | 50.51% | -120.87% | -4.35% | 15.65% | 119.24% | -107.98% | 6405.1% | 1100.02% |
Net Income | -490.87M | -761.5M | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M | -278.16M | 313.75M | 577.22M |
Depreciation & Amortization | 13.37M | 6.43M | 54.37M | 74.44M | 89.69M | 85.55M | 97.03M | 56.67M | 55.66M | 54.81M |
Stock-Based Compensation | 92.82M | 157.75M | 174.84M | 139.87M | 165.72M | 230.65M | 221.68M | 272.08M | 348.24M | 290.05M |
Deferred Taxes | 1.89M | -3.56M | -11.29M | -54.04M | -55.7M | 0 | 0 | -106.76M | -2.2M | -2.53M |
Other Non-Cash Items | 2.91M | -6.84M | -12.61M | 95.75M | 174.24M | 309.24M | 214.93M | 261.94M | 253.42M | 302.79M |
Working Capital Changes | -2.9M | 45.1M | 402.38M | -12.7M | -162.82M | -35.55M | 10.76M | -214.08M | -444.78M | -509.43M |
Change in Receivables | -10.67M | 15.24M | -24.24M | -56.24M | -101.8M | -45.6M | -87.94M | -86.55M | -359.96M | -462.95M |
Change in Inventory | 0 | -22.64M | -32.41M | -35.43M | -26.41M | -34.14M | 18.37M | 13.59M | 8.47M | -1.06M |
Change in Payables | -4.94M | 15.48M | 36.61M | 117.38M | 88.24M | 191.77M | 80.84M | 91.09M | 75.07M | 229.62M |
Cash from Investing | -290.36M | 272.94M | -417.68M | -435.52M | -273.3M | 169.35M | -336.35M | -116.84M | 436.33M | 297.02M |
Capital Expenditures | -104.21M | -126.89M | -140.16M | -70.36M | -76.37M | -72.06M | -62.21M | -34.28M | -58.7M | -71.56M |
CapEx % of Revenue | 115.9% | 169.39% | 63.78% | 14.28% | 9.05% | 6.95% | 3.4% | 1.52% | 1.58% | 1.67% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 120M | -14.82M | 23M | -31.2M | -4.36M | -13.19M | -4.44M | 57.76M | 57.63M | 4.7M |
Cash from Financing | 1.12B | 65.47M | 823.18M | 994.98M | 1.25B | 425.75M | 172.13M | 294.16M | -305.19M | -333.56M |
Debt Issued (Net) | -120M | 0 | -30M | 200M | 500M | 254M | 0 | 0 | -546.95M | -552.65M |
Equity Issued (Net) | 1.16B | 65.47M | 781.9M | 99.5M | 246.27M | 259.36M | 147.46M | 302.95M | 250.03M | 5.49M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -257K | -3.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 83.89M | 0 | 71.28M | 695.48M | 500.85M | -87.61M | 24.67M | -8.79M | -8.27M | 213.6M |
Net Change in Cash | 451.74M▲ 0% | -224.2M▼ 149.6% | 127M▲ 156.6% | -50.58M▼ 139.8% | 323.11M▲ 738.8% | 46.4M▼ 85.6% | -53.67M▼ 215.7% | 153.77M▲ 386.5% | 690.15M▲ 348.8% | 690.17M▲ 0% |
Free Cash Flow | -487M▲ 0% | -689.5M▼ 41.6% | -418.58M▲ 39.3% | -685.32M▼ 63.7% | -718.07M▼ 4.8% | -613.33M▲ 14.6% | 41.95M▲ 106.8% | -42.59M▼ 201.5% | 465.38M▲ 1192.7% | 641.34M▲ 0% |
FCF Margin % | -541.64% | -920.47% | -190.48% | -139.05% | -85.05% | -59.12% | 2.29% | -1.89% | 12.53% | 14.96% |
FCF Growth % | -30.82% | -41.58% | 39.29% | -63.72% | -4.78% | 14.59% | 106.84% | -201.54% | 1192.73% | 950.75% |
FCF per Share | -5.38 | -6.85 | -3.83 | -5.96 | -6.06 | -5.04 | 0.34 | -0.33 | 3.46 | 4.64 |
FCF Conversion (FCF/Net Income) | 0.78x | 0.74x | 0.31x | 0.72x | 0.75x | 0.48x | -0.24x | 0.03x | 1.67x | 1.11x |
Interest Paid | 2.43M | 775K | 172K | 0 | 0 | 0 | 0 | 67.58M | 0 | 215.97M |
Taxes Paid | 114K | 1.07M | 2.57M | 0 | 0 | 0 | 0 | 14.36M | 0 | 1.77M |
ALNY Key Ratios
Alnylam Pharmaceuticals, Inc. (ALNY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -36.54% | -49.63% | -64.66% | -69.92% | -106.31% | -526.14% | - | -414.62% | 73.28% | 98.29% |
Return on Invested Capital (ROIC) | -36.99% | -59.24% | -66.87% | -55.57% | -58.84% | -110.94% | -74.56% | -12.54% | 33.37% | 75.8% |
Gross Margin | 85.13% | 97.59% | 88.6% | 84.16% | 83.4% | 83.73% | 83.02% | 85.62% | 81.77% | 80.89% |
Net Margin | -545.95% | -1016.58% | -403.24% | -174.15% | -101.01% | -109.04% | -24.08% | -12.37% | 8.45% | 13.46% |
Debt / Equity | 0.02x | 0.02x | 0.21x | 0.51x | 1.70x | - | - | 40.89x | 1.62x | 1.18x |
Interest Coverage | - | - | - | -9.13x | -4.96x | -6.23x | -2.58x | -1.66x | 1.99x | 2.02x |
FCF Conversion | 0.78x | 0.74x | 0.31x | 0.72x | 0.75x | 0.48x | -0.24x | 0.03x | 1.67x | 1.11x |
Revenue Growth | 90.66% | -16.69% | 193.36% | 124.28% | 71.31% | 22.88% | 76.23% | 22.97% | 65.19% | 82.57% |
Related:ALNY Dividend History·ALNY Revenue History·ALNY Price History·ALNY P/E History·ALNY Financial Ratios·ALNY Institutional Holders
ALNY SEC Filings & Documents
Alnylam Pharmaceuticals, Inc. (ALNY) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALNY Frequently Asked Questions
Alnylam Pharmaceuticals, Inc. (ALNY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Alnylam Pharmaceuticals, Inc. (ALNY) reported $4.29B in revenue for fiscal year 2025.
Alnylam Pharmaceuticals, Inc. (ALNY) grew revenue by 65.2% over the past year. This is strong growth.
Yes, Alnylam Pharmaceuticals, Inc. (ALNY) is profitable, generating $577.2M in net income for fiscal year 2025 (8.4% net margin).
Dividend & Returns
Alnylam Pharmaceuticals, Inc. (ALNY) has a return on equity (ROE) of 73.3%. This is excellent, indicating efficient use of shareholder capital.
Alnylam Pharmaceuticals, Inc. (ALNY) generated $641.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.